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Purpose: The purpose of this project was to develop an
educational program to nurses as they assume cardiac
monitoring responsibilities on an adult inpatient Blood and
Marrow Transplant unit.
Background: Blood and Marrow patients are at risk for
cardiac toxicities related to the high-dose chemotherapy
they receive as part of their conditioning regimen. By initi-
ating cardiac monitoring on the BMT unit continuity of care
could be maintained by educating Blood and Marrow
Transplant nurses to use the cardiac monitor, manage select
arrhythmias and administer speciﬁc medications to treat the
cardiac situation.
Method:With no cardiac patients or equipment, our biggest
challenge was how to educate nurses to take cardiac
patients on day one after our move. We began our multi-
modal approach with a three day class provided by the
critical care orientation team. We prepared a bucket of
practice strips, led one to one and group learning sessions,
and read 12 lead EKGs to keep our knowledge fresh. All
nurses were required to complete a cardiac arrhythmia test
with an 80% pass threshold. They also attended a mandatory
four hour class run by BMT leadership nurses that included
review of rhythms, Cardiac Monitoring Jeopardy, hands-on
practice with the monitor, scenarios in our hospital's
simulation laboratory. Once telemetry began, staff members
from the hospital's rapid response team rounded daily to
review strip interpretation and consult with nurses as
needed.
Results: A total of 60 nurses completed the program before
initiation of cardiac monitoring. All nurses independently
care for patients onmonitors and usemonitors for vital signs.
Zero patients have transferred to the telemetry unit and RRT
continues support for rhythm checks. We continue to
present the cardiac orientation program to new BMT nurses
along with precepted time with monitored patients to help
them feel prepared for independent practice.512
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Our Adult Blood and Marrow Transplant Program at
a tertiary health care center is a leader in clinical care and
bio-medical research. Patient centered care is the funda-
mental framework of our organization. Many patients from
diverse cultural backgrounds from across our nation and
the world travel here, seeking our care. With this growth
in diversity, it is critical that as health care providers we
understand their particular needs. It is also in our best
interest to provide care that is culturally competent. The
“Advancing effective communication, cultural competence,
and patient and family centered care: A Roadmap for
Hospitals” article, published in August 2010, provides
recommendations to help hospitals address unique patient
needs and comply with existing joint commission
requirements. Firstly, our organization purchased a Culture
Vision database to help health care providers learn about
speciﬁc cultures. Then, our ABMT unit took steps to
embrace culturally competent care by integrating
a cultural knowledge. The nursing staff completed an
assessment of their own healthcare beliefs and practices,
and existing cultural knowledge. Then, we enlisted the
help of nursing staff from different cultural backgroundsto share their experience in the context of their
culture's perception of illness, pain, healing, attitudes
toward authority ﬁgures, use of nonverbal and verbal
communication and its interpretations, spiritual and death
practices, and the role of family within the speciﬁc group.
Unit based nursing grand rounds during staff meetings
included presentations from staff members of Latino,
African, Caribbean, Native American, and Arabic back-
ground. Our focus of presenting unbiased information
about the potential cultural behavior of patient's, resulted
in tearing down barriers and providing optimal patient
care. More importantly, this project helped members of the
nursing staff become more aware of our own traditions
and motivated us to recognize, respect, and take into
account beliefs and practices of our patients. It is no
surprise, that health care providers who understand their
patients’ cultural values, beliefs and practices are more
likely to have positive interactions with their patients and
provide them with culturally acceptable care. When we
embrace other cultures, we learn to understand, accept
and respect differences while fostering trusting relation-
ships with our patients and their family members.513
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Background: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is a life-saving measure for malignant
hematologic disorders. Infection during neutropenia,
however, is amajor cause of transplant relatedmorbidity and
mortality (TRM). The use of granulocyte colony stimulating
factor (GCSF) following HSCT has become a standard of care
in many institutions. Although several retrospective studies
reported that it accelerates neutrophil recovery by 1-6 days,
other meta analyses have failed to demonstrate any signiﬁ-
cant difference in the days of febrile neutropenia. The
CIBMTR working group that reviewed outcomes of patients
who received GCSF during HSCT found no beneﬁt or risk in
those with myeloid leukemia but no improvement in early
TRM despite faster neutrophil recovery. Notably, there have
been no standards published regarding its use or timing of
use in this setting.
Methods: First a review of the published literature on the
use of GCSF in the HSCT setting was performed to
summarize study ﬁndings and recommendations. Second,
a survey was undertaken of the use GCSF at 15 transplant
centers. Questions included: timing of initiation, duration of
therapy, and association with stem cell source and intensity
of conditioning. Finally, a cost analysis was performed using
standard charges to estimate the cost of various GCSF
regimens.
Results: Thus far 8 of the 15 centers have responded. The
volume of transplants/center ranged from 126-519/year. Use
of GCSF is summarized in Table 1.
Cost analysis: The standard charge for GCSF is approx.
$1.00/mcg and ranged from $300-800/dose. Thus cost for
GCSF regimens beginning on D0 vs. D+7 for treatment to
D+14 could be $4200-11200 vs $2100-5600. These are
compared to centers that do not utilize GCSF at all where
the cost is $0.
Conclusions: Despite the lack of supportive data for the use
of GCSF following HSCT, several trials/analyses that
